RGNX
REGENXBIO Inc.
$6.68
-6.83%
2026-10-23
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Key Fundamentals
Forward P/E
-2.46
EPS (TTM)
$-3.78
ROE
-137.6%
Revenue Growth (YoY)
405.7%
Profit Margin
-112.6%
Debt/Equity
349.00
Price/Book
5.58
Beta
0.93
Market Cap
$488.5M
Avg Volume (10D)
1.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$12.08
60D Low
$6.63
Avg Volume
1.4M
Latest Close
$6.68
Get breakout alerts for RGNX
Sign up for Breakout Scanner to receive daily notifications when RGNX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
REGENXBIO Inc. (RGNX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RGNX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RGNX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.